- Home
- COCH vs RADX Comparison
COCH vs RADX Comparison
Compare COCH & RADX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCH
- RADX
- Stock Information
- Founded
- COCH 1995
- RADX 2021
- Country
- COCH United States
- RADX Australia
- Employees
- COCH N/A
- RADX N/A
- Industry
- COCH Blank Checks
- RADX
- Sector
- COCH Finance
- RADX
- Exchange
- COCH Nasdaq
- RADX NYSE
- Market Cap
- COCH 31.6M
- RADX 32.5M
- IPO Year
- COCH N/A
- RADX N/A
- Fundamental
- Price
- COCH $1.47
- RADX $4.25
- Analyst Decision
- COCH Strong Buy
- RADX Strong Buy
- Analyst Count
- COCH 2
- RADX 2
- Target Price
- COCH $9.25
- RADX $13.50
- AVG Volume (30 Days)
- COCH 25.8K
- RADX 22.4K
- Earning Date
- COCH 08-11-2025
- RADX 02-26-2025
- Dividend Yield
- COCH N/A
- RADX N/A
- EPS Growth
- COCH N/A
- RADX N/A
- EPS
- COCH N/A
- RADX N/A
- Revenue
- COCH $212,000.00
- RADX $204,609.00
- Revenue This Year
- COCH $8.04
- RADX N/A
- Revenue Next Year
- COCH $15.39
- RADX N/A
- P/E Ratio
- COCH N/A
- RADX N/A
- Revenue Growth
- COCH N/A
- RADX N/A
- 52 Week Low
- COCH $1.21
- RADX $3.50
- 52 Week High
- COCH $3.99
- RADX $50.82
- Technical
- Relative Strength Index (RSI)
- COCH 48.45
- RADX N/A
- Support Level
- COCH $1.40
- RADX N/A
- Resistance Level
- COCH $1.58
- RADX N/A
- Average True Range (ATR)
- COCH 0.10
- RADX 0.00
- MACD
- COCH 0.01
- RADX 0.00
- Stochastic Oscillator
- COCH 43.74
- RADX 0.00
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.